Aptevo Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Aptevo Therapeutics Inc 's ROA in the second quarter of 2026?
Aptevo Therapeutics Inc recorded a cumulative net loss of $-27 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -93.83%.

However, within the Healthcare sector 770 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4322, from total ROA ranking in the first quarter of 2026 at 5047.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	43.47 %	138.58 %	195.62 %	78.24 %	3.97 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-27	-26	-26	-28	-24
Return On Assets (TTM)	-93.83 %	-99.22 %	-109.7 %	-170.24 %	-178.53 %
APVO's Total Ranking	# 4322	# 5047	# 4552	# 4646	# 4715
Total Assets (TTM) in million	22	20	44	27	16
Seq. Total Assets Change	11.83 %	-54.59 %	62.36 %	74.02 %	85.96 %
Seq. Net Income Change	-	-	-	-	-

APVO's 5 Years Annual ROA >> Back to APVO Management Effectiveness >> Compare APVO ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 356
Sector	# 771
Overall	# 4289

Return On Assets Statistics
High	Average	Low
52.97 %	-66.81 %	-175.68 %
(Mar 31 2023)		(Jun 30 2025)

Financial Statements
Aptevo Therapeutics Inc 's Assets	$ 22 million	APVO's Balance sheet
Aptevo Therapeutics Inc 's Income	$ -6 million	Quarterly APVO's Income Statement
APVO's Income by Division		See APVO's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	181.13 %	-37.24 %	-27.39 %	-39.55 %	5.7 %
Total Assets in million	44	16	25	34	57
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-26	-24	-17	8	-28
Annual Return On Assets	-59.24 %	-154.77 %	-70.09 %	23.46 %	-50.28 %

APVO's 5 Years Annual ROA >> Back to APVO Management Effectiveness >> Compare APVO ROA to its Competitors

More Return On Assets Ratios
APVO's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
APVO's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for APVO's Competitors
Subscribers only: Roa for Aptevo Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for APVO's Customers

You may also want to know
APVO's Roi	APVO's Inventory Turnover Ratio	APVO's Growth Rates	APVO's Dividend Comparisons
	APVO's Profitability Ratios	APVO's Asset Turnover Ratio	APVO's Dividend Growth
APVO's Roe	APVO's Valuation Ratios	APVO's Financial Strength Ratios	APVO's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-08-19T04:23:34+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.